COMP <GO>
XRAY vs INSP // RSI-14 & 200D SMA MOMENTUM
DENTSPLY SIRONA Inc. (NASDAQ) VS. Inspire Medical Systems Inc. (NYSE) • 15-METRIC TALLY: XRAY 3
— INSP 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: XRAY
LAST: $9.61 (+1.80%) • MKT CAP: $1.92B
rsi-technicals
55.1
LAST: $71.18 (+0.30%) • MKT CAP: $2.06B
rsi-technicals
45.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XRAY VS. INSP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XRAY | INSP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.00% | 85.40% | -35.40 | INSP | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.00% | 6.00% | -17.00 | INSP | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 23.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 12.27% | 3.81% | +8.46 | XRAY | /fcf-yield <GO> |
| Operating Margin | -11.50% | 5.60% | -17.10 | INSP | /operating-margins <GO> |
| Net Profit Margin | -16.20% | 15.90% | -32.10 | INSP | /net-margins <GO> |
| Revenue Growth (YoY) | -3.00% | 13.60% | -16.60 | INSP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 6.68% | 0.00% | +6.68 | XRAY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 11.40 | -10.95 | INSP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | INSP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 55.1 | 45.4 | +9.72 | XRAY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 11.9x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.92B | $2.06B | -$142.0M | INSP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XRAY REV | INSP REV | XRAY GROSS % | INSP GROSS % | XRAY FCF | INSP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.68B | $912.0M | 50.0% | 85.4% | $235.0M | $78.5M |
| FY 2024 | $3.79B | $802.8M | 51.6% | 84.7% | $461.0M | $91.1M |
| FY 2023 | $3.96B | $624.8M | — | — | $377.0M | $24.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XRAY // BETA —
INSP // BETA —